🇺🇸 Pegylated liposomal doxorubicin hydrochloride in United States

280 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Alopecia — 41 reports (14.64%)
  2. Malignant Neoplasm Progression — 40 reports (14.29%)
  3. Hair Disorder — 29 reports (10.36%)
  4. Hair Texture Abnormal — 29 reports (10.36%)
  5. Hair Colour Changes — 28 reports (10%)
  6. Madarosis — 25 reports (8.93%)
  7. Off Label Use — 25 reports (8.93%)
  8. Acute Myeloid Leukaemia — 21 reports (7.5%)
  9. Arthropathy — 21 reports (7.5%)
  10. Product Use In Unapproved Indication — 21 reports (7.5%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Pegylated liposomal doxorubicin hydrochloride approved in United States?

Pegylated liposomal doxorubicin hydrochloride does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Pegylated liposomal doxorubicin hydrochloride in United States?

M.D. Anderson Cancer Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.